Bristol-Myers Squibb (NYSE:BMY) Holdings Lifted by Miller Value Partners LLC

Miller Value Partners LLC grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 35.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 108,000 shares of the biopharmaceutical company's stock after purchasing an additional 28,000 shares during the quarter. Bristol-Myers Squibb accounts for 2.6% of Miller Value Partners LLC's investment portfolio, making the stock its 17th biggest position. Miller Value Partners LLC's holdings in Bristol-Myers Squibb were worth $6,108,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Truist Financial Corp lifted its stake in shares of Bristol-Myers Squibb by 3.9% during the fourth quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company's stock worth $90,335,000 after purchasing an additional 60,365 shares in the last quarter. Contravisory Investment Management Inc. purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth about $488,000. Inspire Trust Co. N.A. lifted its stake in shares of Bristol-Myers Squibb by 39.0% in the third quarter. Inspire Trust Co. N.A. now owns 103,500 shares of the biopharmaceutical company's stock worth $5,355,000 after acquiring an additional 29,044 shares in the last quarter. Versant Capital Management Inc boosted its holdings in Bristol-Myers Squibb by 14.0% in the fourth quarter. Versant Capital Management Inc now owns 78,690 shares of the biopharmaceutical company's stock valued at $4,451,000 after purchasing an additional 9,692 shares during the last quarter. Finally, Decker Retirement Planning Inc. acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at approximately $474,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was bought at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now owns 63,932 shares in the company, valued at $3,506,030.88. This trade represents a 2.94 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.09% of the company's stock.

Wall Street Analyst Weigh In

BMY has been the topic of a number of recent analyst reports. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Jefferies Financial Group cut their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Piper Sandler initiated coverage on Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price on the stock. Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Finally, UBS Group cut their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Stock Performance

BMY traded up $0.55 during trading on Monday, reaching $48.45. 18,572,631 shares of the company were exchanged, compared to its average volume of 12,950,880. The stock has a market cap of $98.58 billion, a P/E ratio of -10.96, a PEG ratio of 2.07 and a beta of 0.41. The firm has a 50 day moving average of $56.37 and a 200 day moving average of $56.53. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm's revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the business earned ($4.40) EPS. On average, sell-side analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.12%. Bristol-Myers Squibb's payout ratio is 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.